Gain Therapeutics closed at $1.11 on Nov 4, down 3.48%, within 0.0% of its 52-week closing low. Volume of 226.8K shares was 0.38× its 20-day average (below normal).
Split-adjusted performance: -33.5% over one month, -41.9% over six months, -39.7% over one year.
Short interest was 3.2M shares at the Oct 15 settlement, up 4.4% from the prior report (7.6% of float, 6.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GANXGain Therapeutics | $1.11 | −3.48% | −41.9% | — | — | — | $48.4M | |
| CNTBConnect Biopharma Holdings Limited | $0.7805 | +0.83% | −68.5% | +5666.7% | −624.4% | — | $49.2M | Compare |
| HYPDHyperion DeFi | $3.07 | +0.66% | −15.7% | — | 4009.1% | — | $46.7M | Compare |
| IBIOiBio | $0.8000 | −2.85% | −54.8% | −100.0% | — | — | $51.4M | Compare |
| ANVSAnnovis Bio | $1.21 | +11.01% | −49.6% | — | — | — | $51.6M | Compare |
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | Compare |
| BMEABiomea Fusion | $0.6119 | −1.91% | −61.8% | — | — | — | $44.4M | Compare |
| ATNMActinium Pharmaceuticals | $1.41 | +0.71% | +13.7% | — | 79.7% | 3.9 | $44.3M | Compare |
| HOWLWerewolf Therapeutics | $1.09 | +1.87% | +67.6% | — | 17.5% | — | $53.0M | Compare |
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
